4th Quarter - Termination

NVG, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—
Terminated
Dec 31, 2021

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Orphan Drug Tax Credit provisions in the Build Back Better Act (H.R. 5376).

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
ANDREA LARUE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th)

Health Issues HCR

FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
ANDREA LARUE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

FY 2022 LHHS Appropriations report language on Wilson's Disease, Myasthenia Gravis; Neuromyelitis Optica Spectrum Disorder (NMOSD); Low volume DRG payments for rare disease therapies and home infusion.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.